Clinical Trial Update: A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-108 in Patients With Onychomycosis [Phase 2]

View source ↗

Summary

A Phase 2 dose-ranging study evaluating the safety and efficacy of IDP-108 for onychomycosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Onychomycosis

Drugs mentioned

• IDP-108

Snippet

Sponsor: Dow Pharmaceutical Sciences | Conditions: Onychomycosis | Phase 2 | Status: COMPLETED